ALKS Share Price Performance
ALKS Community Fair Values
- US$53.31FV50.2% undervalued intrinsic discount3.48%Revenue growth p.a.0users have liked this narrative1users have commented on this narrative1users have followed this narrative10 days ago author updated this narrative
- US$41.44FV35.9% undervalued intrinsic discount-1.54%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative5users have followed this narrative3 days ago author updated this narrative
- US$30.00FV11.5% undervalued intrinsic discount-4.11%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrative17 days ago author updated this narrative
Recent ALKS News & Updates
No updates
Alkermes plc Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 2.11
- Gross Margin
- 85.13%
- Net Profit Margin
- 23.12%
- Debt/Equity Ratio
- 0%
Alkermes plc Competitors
About ALKS
- Founded
- 1987
- Employees
- 1800
- CEO
- WebsiteView website
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Irish Market Performance
- 7 Days: -4.3%
- 3 Months: 3.7%
- 1 Year: 19.2%
- Year to Date: 14.2%
Over the last 7 days, the market has dropped 4.3%, driven by losses in the Financials and Consumer Staples sectors of 5.4% and 7.9%, respectively. As for the longer term, the market has actually risen by 19% in the last year. Earnings are forecast to grow by 8.8% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading